Creatine Supplementation in Female Collegiate Dancers

Effects of Creatine Supplementation on Performance, Body Composition and Mental Health in Female Collegiate Dancers

This study will be a 6 week creatine supplementation intervention with performance familiarization and pre and post testing. Participants will report to the human performance laboratory (HPL) for baseline to read and sign an informed consent explaining the procedures and potential risks and benefits of participation. Participants will then complete a physical activity readiness questionnaire (PAR-Q) prior to performing any physical tasks. Participants will also be asked to complete testing below in the order described. Participants will become familiar with the pre/post performance tests, which include isokinetic testing, medicine ball throw, vertical jump, and Wingate testing. Twenty-four hours following visit 1, participants will return to the HPL for visit 2 where they will undergo a second familiarization session for the isokinetic testing and Wingate testing only - these two tests require individuals to provide maximal physical efforts and research suggests that participants should perform multiple familiarization trials before beginning experimental trials. At least 72 hours following visit 2, participants will return to the HPL for visit 3 to perform the baseline performance assessments. Following the baseline assessments, participants will be divided into two supplementation groups: creatine and placebo (maltodextrin). These groups will be randomized and matched based on body mass, hours of dance training per week, meat intake, and menstrual cycle phase. Participants will be asked to consume one of the two supplements daily for 42 consecutive days and maintain their regular dance training and eating behaviors. Participants will report to the HPL daily to receive their supplement between the hours of 12pm and 2pm. Following the last day of supplement consumption, participants will report to the HPL to perform post-testing assessments which will be identical to pre testing.

Study Overview

• Status: Completed
• Conditions: Creatine
• Intervention / Treatment: Dietary supplement: Creatine; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Idaho
    • Moscow, Idaho, United States, 83844
      • University of Idaho

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 24 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Collegiate dance major or minor

Exclusion Criteria:

• Injured within the past 6 months
• Currently consuming creatine supplements

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Creatine Supplementation	Dietary supplement: Creatine; Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
Placebo Comparator: Placebo Supplementation	Dietary supplement: Placebo; Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in fat mass from baseline after 42 days	Dual energy x-ray absorptiometry used to assess fat mass (% and kg)	Change from baseline fat mass at 42 days
Change in lean mass from baseline after 42 days	Dual energy x-ray absorptiometry used to assess lean mass (% and kg)	Change from baseline lean mass at 42 days
Change in visceral adipose tissue from baseline after 42 days	Dual energy x-ray absorptiometry used to assess visceral adipose tissue (cm2)	Change from baseline visceral adipose tissue at 42 days
Change in peak muscular strength from baseline after 42 days	Cybex isokinetic dynamometry used to assess peak muscular strength (W)	Change from baseline peak muscular strength at 42 days
Change in peak vertical jump height from baseline after 42 days	Cybex isokinetic dynamometry used to assess vertical jump height (in)	Change from baseline peak vertical jump height at 42 days
Change in upper body muscular power from baseline after 42 days	Seated medicine ball toss used to assess upper body muscular power (in)	Change from baseline upper body muscular power at 42 days
Change in muscular power from baseline after 42 days	Wingate anaerobic power test used to assess muscular power (W)	Change from baseline muscular lower at 42 days
Change in depression, anxiety and stress score from baseline after 42 days	Depression, anxiety and stress scale (from 0, normal to 42, extremely severe) used to assess depression, anxiety and stress	Change from baseline depression, anxiety and stress at 42 days
Change in cognitive performance from baseline after 42 days	NIH Toolbox for the assessment of Neurological and Behavioral Function ipad application to assess fluid cognitive measures including executive function, attention, episodic memory, processing speed, and working memory.	Change from baseline cognitive performance at 42 days

Collaborators and Investigators

• Sponsor: University of Idaho

Study record dates

Study Major Dates

• Study Start (Actual): September 27, 2021
• Primary Completion (Actual): January 30, 2022
• Study Completion (Actual): January 30, 2022

Study Registration Dates

• First Submitted: October 26, 2021
• First Submitted That Met QC Criteria: October 26, 2021
• First Posted (Actual): November 5, 2021

Study Record Updates

• Last Update Posted (Actual): August 15, 2022
• Last Update Submitted That Met QC Criteria: August 11, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: creatine, body composition, dancer, cognition
• Other Study ID Numbers: 21-181

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No